Determination of optimal 68 Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT
- 28 December 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (6) , 2086-2095
Abstract
Background 68 Ga-PSMA PET/CT has been widely used in patients with prostate cancer. Due to the limited axial field of view of conventional PET scanners, whole-body dynamic 68 Ga-PSMA PET/CT has not been performed. We investigated the time-activity curves (TACs) of prostate cancer pathological lesions and physiologic bladder activity to determine the optimal 68 Ga-PSMA PET/CT imaging time by total-body (TB) PET/CT. Methods Dynamic TB-PET performed on 11 patients with prostate cancer was analyzed. TACs were obtained by drawing regions of interest in normal organs and pathological lesions (primary prostate lesions and lymph nodes and bone metastases). We evaluated the 68 Ga-PSMA uptake pattern of normal organs, urinary bladder, and pathological lesions. Results The urinary bladder TAC increased slowly between 180 and 330 s post-injection and then rapidly between 5.5 and 60.0 min post-injection. The pathological lesion uptake increased rapidly during the first 5 min post-injection and then slowly through the remaining 55 min. Six minutes post-injection was the optimal time with the highest pathological lesion SUVmean values still higher than the urinary bladder activity value. However, these prostate lesion, lymph node metastasis, and bone metastasis SUVmean values were one-third, one-half, and one-half the corresponding values 60 min post-injection, suggesting that early imaging might miss low PSMA uptake lesions. A minimum of 35 min post-injection was required for the pathological lesions to have SUVmean values similar to the corresponding values at 60 min post-injection (all P > 0.05), even though the pathological lesion SUVmean values showed a continuous upward trend through the 60 min. Conclusions Combining early dynamic 68 Ga-PSMA PET (75–360 s) and conventional static imaging 60 min post-injection could avoid the urinary bladder activity interference to better detect pathological lesions and lesions with relatively low PSMA uptake. The pathological lesion SUVmean values at 35–59 min and 60 min post-injection were similar, so 68 Ga-PSMA PET imaging could also be made at 35–59 min post-injection.Keywords
This publication has 18 references indexed in Scilit:
- First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*Journal of Nuclear Medicine, 2019
- Total-body imaging: Transforming the role of positron emission tomographyScience Translational Medicine, 2017
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2017
- Quantitative image reconstruction for total-body PET imaging using the 2-meter long EXPLORER scannerPhysics in Medicine & Biology, 2017
- Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imagingNuclear Medicine Communications, 2016
- Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imagingNuclear Medicine Communications, 2015
- Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012